Neuraxis (NRXS) Net Margin (2022 - 2025)

Neuraxis (NRXS) posted Net Margin of 196.62% for Q4 2025, up 31.28% sequentially from 286.11% in Q3 2025, and up 1547.0% YoY from 11.94% in Q4 2024.

Neuraxis (NRXS) Net Margin (2022 - 2025) Analysis & Trends

Neuraxis has reported Net Margin for 4 years, with the latest figure at 196.62% in Q4 2025.

Quarterly Net Margin rose 1547.0% year-over-year to 196.62% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 241.37% (up 7334.0% YoY) and the FY2025 annual result came in at 241.37%, up 7334.0% from the prior year.
Net Margin grew to 196.62% in Q4 2025 per NRXS's latest filing, from 286.11% in the prior quarter.
Over five years, Net Margin peaked at 33.67% in Q4 2022 and troughed at 1027.18% in Q3 2023.
A 4-year average of 363.03% and a median of 278.26% in 2025 frame the typical range for Net Margin.
The sharpest annual moves came in 2023 and 2024: Net Margin sank 96609 bps in 2023, then jumped 78767 bps in 2024.
Over 4 years, Net Margin stood at 33.67% in 2022, then sank by 2869 bps to 999.76% in 2023, then surged by 79 bps to 212.09% in 2024, then advanced by 7 bps to 196.62% in 2025.
According to Business Quant data, Net Margin over the past three periods registered 196.62%, 286.11%, and 212.27% for Q4 2025, Q3 2025, and Q2 2025 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Net Margin (Qtr)
1	Vertex Pharmaceuticals	138.41 Bn	130.56 Bn	2.84 Bn	32.99%
2	Regeneron Pharmaceuticals	86.12 Bn	78.12 Bn	3.93 Bn	30.23%
3	Argenx Se	64.41 Bn	59.23 Bn	1.37 Bn	31.16%
4	Moderna	57.56 Bn	52.43 Bn	52.00 Mn	-539.31%
5	BeOne Medicines	42.06 Bn	36.96 Bn	1.53 Bn	13.90%
6	Alnylam Pharmaceuticals	30.95 Bn	27.65 Bn	992.69 Mn	12.74%
7	BioNTech SE	27.48 Bn	9.09 Bn	668.28 Mn	-16.51%
8	Insmed	27.31 Bn	26.15 Bn	358.27 Mn	-3.12%
9	Royalty Pharma	27.04 Bn	26.20 Bn	-	12.09%
10	Neuraxis	78.80 Mn	70.48 Mn	-	-

Download Data